全文获取类型
收费全文 | 45786篇 |
免费 | 4059篇 |
国内免费 | 183篇 |
学科分类
医药卫生 | 50028篇 |
出版年
2023年 | 154篇 |
2022年 | 154篇 |
2021年 | 851篇 |
2020年 | 647篇 |
2019年 | 1191篇 |
2018年 | 1261篇 |
2017年 | 1040篇 |
2016年 | 1105篇 |
2015年 | 1364篇 |
2014年 | 1737篇 |
2013年 | 2399篇 |
2012年 | 3126篇 |
2011年 | 3305篇 |
2010年 | 1995篇 |
2009年 | 1811篇 |
2008年 | 2902篇 |
2007年 | 3017篇 |
2006年 | 2900篇 |
2005年 | 2902篇 |
2004年 | 2810篇 |
2003年 | 2714篇 |
2002年 | 2827篇 |
2001年 | 413篇 |
2000年 | 319篇 |
1999年 | 437篇 |
1998年 | 579篇 |
1997年 | 526篇 |
1996年 | 421篇 |
1995年 | 438篇 |
1994年 | 352篇 |
1993年 | 352篇 |
1992年 | 222篇 |
1991年 | 245篇 |
1990年 | 201篇 |
1989年 | 193篇 |
1988年 | 173篇 |
1987年 | 175篇 |
1986年 | 185篇 |
1985年 | 168篇 |
1984年 | 207篇 |
1983年 | 160篇 |
1982年 | 229篇 |
1981年 | 213篇 |
1980年 | 187篇 |
1979年 | 121篇 |
1978年 | 138篇 |
1977年 | 115篇 |
1976年 | 90篇 |
1974年 | 79篇 |
1972年 | 81篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
2.
Jean‐Franois Etter 《Addiction (Abingdon, England)》2019,114(12):2252-2256
3.
4.
5.
6.
The National DMEFP Conference Team which consists of the following authors Charlene M. Dewey Teri L. Turner Linda Perkowski Jean Bailey Larry D. Gruppen 《Medical teacher》2016,38(2):141-149
Medical education fellowship programs (MEFPs) are a form of faculty development contributing to an organization’s educational mission and participants’ career development. Building an MEFP requires a systematic design, implementation, and evaluation approach which aligns institutional and individual faculty goals. Implementing an MEFP requires a team of committed individuals who provide expertise, guidance, and mentoring. Qualified MEFP directors should utilize instructional methods that promote individual and institutional short and long term growth. Directors must balance the use of traditional design, implementation, and evaluation methodologies with advancing trends that may support or threaten the acceptability and sustainability of the program. Drawing on the expertise of 28 MEFP directors, we provide twelve tips as a guide to those implementing, sustaining, and/or growing a successful MEFP whose value is demonstrated by its impacts on participants, learners, patients, teaching faculty, institutions, the greater medical education community, and the population’s health. 相似文献
7.
8.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
9.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
10.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献